High-dose chemotherapy followed by reinfusion of autologous stem cells harvested from peripheral blood has been increasingly applied for a variety of disorders.Background:
The critical importance of cell dose in the clinical outcome, after transplant, has motivated the need to develop techniques aimed at reducing cell losses and increasing reproducibility.Objectives:
The aim of this study is to evaluate the efficacy of the Sepax S-100 device to process thawed HPC-A products in comparison with manual procedure.Methods/Materials:
We have analysed viability, total nucleated cells (TNC), haematopoietic progenitors and CD34+ cells recovery.Results:
The TNC and CD34+ cells recovery in the automatic procedure was of 91·9% (73–100; SD ± 12·60) and 86·7% (69–100; SD ± 10·21), respectively. Instead the recovery of TNC and CD34+ cells using the manual method was of 84·7% (47–100; SD ± 22·9) and 80·29% (23–100; SD ± 25·96).Results:
The results, obtained from the assessment of viability of CD34+ both 7-AAD)+ and AnnV+ showed a high percentage of necrosis and apoptosis in this cell subset by using the manual procedure in respect to the Sepax automated system.Conclusion:
Overall, our data suggest that the automated washing procedure is safe and suitable for processing of thawed HPC-A products and can be daily used in clinical routine.